Home › Funds › OBERWEIS ASSET MANAGEMENT INC/ › HALO

OBERWEIS ASSET MANAGEMENT INC/ position in HALO

HALOZYME THERAPEUTICS INC · Health Care

OBERWEIS ASSET MANAGEMENT INC/ reported holding 383,508 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$42.3M, representing 0.96% of its reported portfolio and ranking #19 among its reported holdings. OBERWEIS ASSET MANAGEMENT INC/ has disclosed HALO holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)383.51K sh
Reported value held$42.34M
Portfolio Weight0.96%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How OBERWEIS ASSET MANAGEMENT INC/'s HALO position evolved

OBERWEIS ASSET MANAGEMENT INC/ first disclosed a stake in HALO in Q3 2023 at 50,500 shares (US$1.9M). The position peaked in Q3 2026 at 383,508 shares, worth US$42.3M. Across 8 filings, OBERWEIS ASSET MANAGEMENT INC/ increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 383,508 shares valued at US$42.3M — an increase of 62,478 shares quarter over quarter.. Notable position changes include a 91% increase in Q4 2023 (shares rose 10% over the following quarter), a 87% increase in Q1 2026 (shares rose 21% over the following quarter), a 46% increase in Q2 2026 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 50.50K $1.93M New
Q4 2023 96.30K $3.56M Add
Q2 2025 182.20K $9.48M New
Q3 2025 117.58K $8.62M Reduce
Q4 2025 117.58K $7.91M Hold
Q1 2026 219.93K $14.21M Add
Q2 2026 321.03K $25.13M Add
Q3 2026 383.51K $42.34M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$244.3M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has OBERWEIS ASSET MANAGEMENT INC/ held HALO?

OBERWEIS ASSET MANAGEMENT INC/ has disclosed HALO holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

What is OBERWEIS ASSET MANAGEMENT INC/'s current position in HALO?

As of Q3 2026, OBERWEIS ASSET MANAGEMENT INC/ holds 383.51K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $42.34M, representing 0.96% of its reported portfolio and ranking #19.

Has OBERWEIS ASSET MANAGEMENT INC/ been buying or selling HALO?

In the latest 13F filing (Q3 2026), OBERWEIS ASSET MANAGEMENT INC/ increased its position in HALO. The position peaked in Q3 2026 at 383.51K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.